Enel Health®Atlas
Sign in
Enel Health®Atlas
Browse libraries

Not medical advice. The Atlas is not a substitute for a clinician who can examine you.

Matrixyl

Palmitoyl Pentapeptide-4 (Sederma)

Evidence grade 2 of 5, Thin. Read how the Atlas grades evidence.

Topical cosmetic matrikine (pal-KTTKS) whose human evidence rests mainly on small, manufacturer-sponsored split-face trials, chiefly Robinson et al. 2005 (93 women, Procter & Gamble laboratories), which reported statistically significant but modest reductions in fine lines versus vehicle. Independent peer-reviewed data are thinner than the marketing implies and effect sizes are small relative to retinoids, so preliminary-human (grade 2) is the honest grade rather than the strong-RCT tier.

FDA
Not FDA-approved. Cosmetics and their ingredients require no FDA premarket approval (only color additives do); Matrixyl is a legally marketed cosmetic ingredient regulated post-market, not an approved drug.
WADA
Not prohibited (topical cosmetic, not on the WADA prohibited list)

Reference only. Not medical advice.

What can go wrong

Low risk, topical; generally well tolerated, efficacy modest and slower than prescription retinoids.

Talk to a clinician before taking this. The Atlas can tell you what has been studied about Matrixyl. It cannot tell you how it would interact with your body, your history, or anything else you are taking, and nothing on this page is a reason to start.

A widely used synthetic cosmetic peptide (pal-KTTKS) marketed to signal collagen and extracellular-matrix renewal. Human data supporting modest wrinkle improvement come mainly from small manufacturer-sponsored trials; it is a legal cosmetic ingredient, not an FDA-approved drug.

What people take it for

These are the reasons people give for taking it. They are not effects it has been shown to have.

  • Wrinkle reduction
  • Collagen stimulation
  • Anti-aging skincare

How it is supposed to work

Matrixyl takes a completely different route to smoother skin than the Botox-style peptides. Instead of relaxing muscles, it tells the skin to rebuild itself. When skin ages, its collagen breaks into small fragments, and the body reads those fragments as a signal to make fresh collagen. Matrixyl is a synthetic copy of one of those signal fragments, so applied to skin it mimics the body’s own repair message, prompting the collagen-making cells to produce more collagen and other support proteins, even without any actual damage to trigger it.

Matrixyl is a synthetic signal peptide, five amino acids known as KTTKS, a fragment of procollagen, attached to a fatty-acid palmitoyl chain. That fatty tail is the clever part, because it lets the otherwise skin-impermeable peptide pass through the skin barrier and reach the cells that build collagen. Launched in 2000, it is sold in several generations, including Matrixyl, Matrixyl 3000 and Synthe’6.

Type
Cosmetic signal peptide
Mimics
A collagen fragment
Effect
Stimulates collagen
Penetration
Solved by fatty tail
Evidence
Best of cosmetic peptides
Status
Cosmetic, not a drug

Signals Skin To Build Collagen, And Actually Gets In

Matrixyl is the cosmetic-peptide success story, at least relatively speaking, and it is instructive to compare it with the Botox-style peptides like Argireline. Two things set it apart. First, it solved the penetration problem that limits most topical peptides: attaching a fatty-acid tail to the active fragment lets it actually cross the skin barrier, where a bare peptide would not. Second, and more importantly, it has the most replicated clinical evidence of any cosmetic peptide, with several placebo-controlled split-face trials showing measurable reductions in wrinkles and fine lines, typically in the range of ten to thirty percent over a couple of months. That is a genuinely better evidence base than most of its category. The honest qualifiers still matter: the results are modest improvements rather than miracles and are no substitute for proven actives like retinoids or for procedures, a good deal of the supporting research is industry-funded, the effect depends on using an adequate concentration in a decent formulation, and the precise receptor it acts on has not been pinned down. It remains a cosmetic, not an approved drug.

Safety in detail

Marketed as a cosmetic, not a therapeutic. Skin-benefit claims are associated with mostly industry-sponsored studies of small effect size; treat wrinkle-reduction figures cited by brands as manufacturer claims rather than independent consensus.

  • It has an excellent safety profile: non-irritating and, unlike retinoids, it does not promote inflammation.
  • It causes no muscle paralysis, since it does not act on nerves or muscle.
  • It is suitable for daily use and all skin types and has been used over the counter for over fifteen years.
  • Its main limitation is modest, concentration-dependent efficacy, not any harm.
  • It is a well-tolerated cosmetic ingredient.

Children and teenagers

Matrixyl is a cosmetic anti-wrinkle and collagen ingredient with no pediatric relevance, since children do not have collagen-loss or wrinkle concerns. While low-risk on skin, there is no reason for pediatric use, and anti-aging cosmetic marketing aimed at young people is itself a concern. There is no appropriate pediatric use.

What people get wrong

Nothing recorded here yet. There is almost certainly something people get wrong about this one, and the blank space means we have not written it down, not that the record is clean.

Who profits, and who pushes back

Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.

Matrixyl’s economy is the mainstream cosmetic-skincare industry: the specialty ingredient maker and the vast over-the-counter market of anti-aging serums and creams built around it over more than fifteen years, making it one of the most popular anti-aging actives. Its better-than-average evidence is itself part of the marketing, and the benefit still depends heavily on concentration and formulation.

How we got here

Palmitoyl pentapeptide-4 was developed and trademarked as Matrixyl by the French cosmetic-active manufacturer Sederma SAS, which launched it in 2000 as a matrikine designed to signal collagen and extracellular-matrix renewal by mimicking a fragment of type I collagen. It was originally catalogued under the INCI name palmitoyl pentapeptide-3 and renamed palmitoyl pentapeptide-4 in 2006 when the cosmetic naming system was reconciled, though the molecule (pal-KTTKS) never changed. Sederma later extended the Matrixyl brand into separate, chemically different products, Matrixyl 3000 (palmitoyl tripeptide-1 plus palmitoyl tetrapeptide-7) and Matrixyl synthe'6 (palmitoyl tripeptide-38), so the shared brand name spans several distinct peptides whose clinical data do not automatically transfer to one another.

Building on the discovery that a procollagen fragment signals collagen production, a French ingredient company launched Matrixyl in 2000, attaching a fatty-acid chain to solve the penetration problem that defeats most topical peptides. Multiple placebo-controlled trials over the following years built the most replicated evidence base of any cosmetic peptide, and next-generation versions like Matrixyl 3000 and Synthe’6 followed. It has remained a top anti-aging ingredient for over fifteen years.

  1. 1993A procollagen fragment is shown to signal collagen production.
  2. 2000Matrixyl launches, using a fatty-acid chain to solve penetration.
  3. 2000sPlacebo-controlled trials build its evidence base.
  4. 2000s-2010sNext-generation variants like Matrixyl 3000 and Synthe’6 arrive.
  5. ongoingIt remains one of the most popular anti-aging ingredients.

The numbers behind the grade

Type
Cosmetic signal peptide
Mimics
Collagen fragment
Effect
Stimulates collagen
Penetration
Solved
Evidence
Best of category
Status
Cosmetic

The people taking it

The most-studied cosmetic peptide, a collagen-stimulating signal peptide that mimics the skin’s own repair message and cleverly solves the penetration problem, delivering real but modest wrinkle improvement.

Matrixyl’s users are mainstream anti-aging skincare consumers focused on wrinkles and collagen, the peptide-skincare and clean-beauty crowd, and people who want a gentle, non-irritating anti-ager as an alternative or complement to retinoids. It reaches a broad, largely adult cosmetic audience.

A widely-used over-the-counter anti-aging cosmetic ingredient for over fifteen years, the best-evidenced cosmetic peptide, delivering measurable but modest wrinkle reduction. Gentle and safe, with a concentration-dependent effect.

Set against the alternatives

The key contrast is with Argireline: that peptide relaxes expression muscles like a gentle Botox, penetrates poorly and has weak, unclear evidence, while Matrixyl stimulates collagen, solved its penetration with a fatty tail and has a better, replicated evidence base, and because they work on different pathways the two are often combined. Against retinoids, the gold-standard anti-ager, Matrixyl is gentler but more modest, a complement rather than a replacement. Against its own later variants like Matrixyl 3000 and Synthe’6, it is the original of a multi-peptide family. And against copper peptides and collagen approaches, it is the best-studied of the collagen-supporting options. Its strength is real, replicated, if modest, evidence; its limit is that the effect stays small.

What we do not know

  • Which fibroblast receptor it acts on, still not definitively identified.
  • How much of the effect comes from concentration and formulation versus the peptide itself.
  • What the effect size looks like in independent, non-industry trials.
  • Which variant or combination works best.

What could change

Next-generation variantsMulti-peptide versions extend the original approach.Better deliveryFormulation work continues to improve penetration and effect.Independent trialsMore non-industry studies would strengthen the evidence.Signal-peptide categoryIt anchors a growing class of collagen-signaling cosmetics.

The market for this

What follows describes how this is bought and sold. It is not a buying guide and it is not an endorsement of any seller.

Matrixyl is a widely available and, for a cosmetic peptide, well-evidenced over-the-counter anti-ager: the best-studied of its kind, safe and gentle, with real but modest results. Look for an adequate concentration in a decent formulation, the key variable, and set expectations for modest improvement rather than retinoid-level or procedure-level change. It is a sensible, legitimate cosmetic choice and one of the better cosmetic peptides.

Matrixyl is inexpensive to moderately priced across a wide range of over-the-counter products, and it is broadly accessible.

Matrixyl comes from a specialty cosmetic-ingredient maker and appears in countless over-the-counter products, with concentration and formulation quality varying in ways that drive any benefit.

Cosmetic-ingredient makerA specialty manufacturer produces the Matrixyl family of peptides.Over-the-counter skincareIt appears in a vast range of anti-aging serums and creams.Variable formulationsConcentration and formulation vary widely and drive the actual effect.

What this entry does not yet cover

What follows is unfinished work on our side, not a finding about Matrixyl.

Nothing outstanding on this one.

Sources

The studies that matter

  • Collagen-signal mechanismin vitro

    Its KTTKS sequence mimics a procollagen fragment, signaling fibroblasts to make more collagen and elastin, with large collagen increases in skin-explant models.

  • Penetration solutionestablished

    Attaching a fatty-acid chain lets the otherwise impermeable peptide cross the skin barrier, unlike most topical peptides.

  • Clinical trialsmultiple RCTs

    Several placebo-controlled split-face trials showed measurable wrinkle and fine-line reduction, roughly ten to thirty percent over a couple of months.

  • Best-evidenced peptidereviews

    Matrixyl has the most replicated clinical evidence of any cosmetic peptide, though much of it is industry-funded.

  • Cosmetic status2026

    No palmitoyl peptide has FDA drug approval; Matrixyl is regulated as a cosmetic, with modest, concentration-dependent effects.